Patient Selection for Mepolizumab in Severe Asthma: Time for Reappraisal?

Affiliations

¹ Department of Respiratory Medicine, Seinäjoki Central Hospital, Seinäjoki, Finland; Faculty of Medicine and Health Technology, University of Tampere, Tampere, Finland; Department of Internal Medicine and Clinical Nutrition, Krefting Research Centre, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden. Electronic address: hannu.kankaanranta@tuni.fi.
² Department of Respiratory Medicine, Seinäjoki Central Hospital, Seinäjoki, Finland. Electronic address: pinja.ilmarinen@epshp.fi.

Editorial

Hannu Kankaanranta et al. J Allergy Clin Immunol Pract. 2020 Oct.

. 2020 Oct;8(9):3009-3010.

doi: 10.1016/j.jaip.2020.05.036.

¹ Department of Respiratory Medicine, Seinäjoki Central Hospital, Seinäjoki, Finland; Faculty of Medicine and Health Technology, University of Tampere, Tampere, Finland; Department of Internal Medicine and Clinical Nutrition, Krefting Research Centre, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden. Electronic address: hannu.kankaanranta@tuni.fi.
² Department of Respiratory Medicine, Seinäjoki Central Hospital, Seinäjoki, Finland. Electronic address: pinja.ilmarinen@epshp.fi.

No abstract available

Comment on

Treatment Eligibility of Real-Life Mepolizumab-Treated Severe Asthma Patients.
Richards LB, van Bragt JJMH, Aarab R, Longo C, Neerincx AH, Sont JK, Weersink EJM, Braunstahl GJ, Brinke AT, Bel EHD, Maitland-van der Zee AH. Richards LB, et al. J Allergy Clin Immunol Pract. 2020 Oct;8(9):2999-3008.e1. doi: 10.1016/j.jaip.2020.04.029. Epub 2020 Apr 25. J Allergy Clin Immunol Pract. 2020. PMID: 32344189